The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AbbVie; AstraZeneca; Janssen; Sunesis Pharmaceuticals
Speakers' Bureau - Janssen
Research Funding - AbbVie; Janssen
Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
 
Paul M. Barr
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb/Celgene; Genentech; Infinity Pharmaceuticals; Janssen; MEI Pharma; Merck; MorphoSys; Novartis; Pharmacyclics; Seagen; TG Therapeutics
Research Funding - AstraZeneca (Inst); Pharmacyclics (Inst)
 
Carolyn Owen
Honoraria - Abbvie; AstraZeneca; Janssen; Novartis Canada Pharmaceuticals Inc; Roche Canada; Teva
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Acerta Pharma/AstraZeneca (Inst); Celgene (Inst); Gilead Sciences (Inst); Janssen (Inst); Roche Canada (Inst)
 
Tadeusz Robak
Honoraria - Abbvie
Consulting or Advisory Role - Abbvie; Abbvie
Research Funding - Abbvie/Genentech (Inst)
 
Alessandra Tedeschi
Consulting or Advisory Role - AbbVie; AstraZeneca; BeiGene; Janssen; Sunesis Pharmaceuticals
Speakers' Bureau - AbbVie; Janssen
 
Osnat Bairey
Consulting or Advisory Role - AbbVie; AstraZeneca; Janssen
Research Funding - Janssen
 
Jan Andreas Burger
Honoraria - Janssen
Consulting or Advisory Role - Janssen
Speakers' Bureau - Gilead Sciences; Janssen; Novartis; Pharmacyclics; TG Therapeutics
Research Funding - BeiGene; Gilead Sciences; Pharmacyclics; TG Therapeutics
Travel, Accommodations, Expenses - Gilead Sciences; Janssen; Novartis; Pharmacyclics; TG Therapeutics
 
Peter Hillmen
Honoraria - Abbvie; Janssen; Roche
Research Funding - Abbvie (Inst); Gilead Sciences (Inst); Janssen (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Abbvie; Janssen
 
Steve E. Coutre
Stock and Other Ownership Interests - Abbvie/Pharmacyclics (I)
Honoraria - Abbvie; Janssen Oncology; Pharmacyclics
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; AstraZeneca; BeiGene; Genentech/Roche; Janssen Oncology; Pharmacyclics
Research Funding - Abbvie (Inst); Acerta Pharma/AstraZeneca (Inst); Janssen Oncology (Inst); Kite/Gilead; Pharmacyclics (Inst)
Expert Testimony - Genentech; Pharmacyclics
Travel, Accommodations, Expenses - abbvie; BeiGene; Celgene; Genentech; Janssen Oncology; Pharmacyclics
 
Stephen Devereux
No Relationships to Disclose
 
Sebastian Grosicki
No Relationships to Disclose
 
Helen McCarthy
Honoraria - Janssen
Consulting or Advisory Role - AbbVie; Janssen
Travel, Accommodations, Expenses - Janssen
 
Jianyong Li
No Relationships to Disclose
 
David Simpson
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Honoraria - AbbVie; Janssen
Research Funding - AbbVie; Acerta Pharma; Amgen; BeiGene; Celgene; GlaxoSmithKline; Janssen; Merck Sharp & Dohme; Pharmacyclics; Roche; Sanofi
Travel, Accommodations, Expenses - AbbVie; Janssen
 
Fritz C. Offner
No Relationships to Disclose
 
Carol Moreno
No Relationships to Disclose
 
Sandra Dai
Employment - Pharmacyclics
Stock and Other Ownership Interests - AbbVie; Bristol-Myers Squibb; Exelixis; Gilead Sciences; GlaxoSmithKline; Revance Therapeutics
 
Anita Szoke
Employment - Pharmacyclics
Stock and Other Ownership Interests - AbbVie
 
James P. Dean
Employment - Pharmacyclics
Stock and Other Ownership Interests - Abbvie
 
Thomas J. Kipps
Employment - Moores Cancer Center
Stock and Other Ownership Interests - Oncternal Therapeutics, Inc
Honoraria - Abbvie; AstraZeneca; Dava Oncology; Genentech; Gilead Sciences; Janssen; Pharmacyclics
Consulting or Advisory Role - Abbvie; Dava Oncology; Genentech; Janssen; Pharmacyclics
Speakers' Bureau - Abbvie/Genentech; DAVA Pharmaceuticals; Gilead Sciences; Pharmacyclics/Janssen; Verastem/Pharmacyclics
Research Funding - Breast Cancer Research Foundation (Inst); California Institute for Regenerative Medicine (CIRM) (Inst); Leukemia and Lymphoma Society (Inst); National Cancer Institute (Inst); NIH (Inst); Oncternal Therapeutics, Inc (Inst); Pharmacyclics/Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Cirmtuzumab was developed by Thomas J. Kipps in the Thomas J. Kipps laboratory and licensed by the University of California to Oncternal Therapeutics, Inc., which provided stock options and research funding to the Thomas J. Kipps laboratory. (Inst)
Travel, Accommodations, Expenses - Abbvie/Pharmacyclics; AstraZeneca; Breast Cancer Research Foundation; Celgene; Dava Oncology; Genentech/Roche; Gilead Sciences; Janssen; TG Therapeutics; Verastem
 
Paolo Ghia
Honoraria - AbbVie; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; ArQule; BeiGene; Gilead Sciences; Janssen; Juno/Celgene; Loxo/Lilly; Sunesis Pharmaceuticals
Consulting or Advisory Role - AbbVie; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; ArQule; BeiGene; Gilead Sciences; Janssen; Juno/Celgene; Loxo/Lilly; Sunesis Pharmaceuticals
Research Funding - AbbVie; Gilead Sciences; Janssen; Novartis; Sunesis Pharmaceuticals